Analysis of cartilage-derived retinoic acid-sensitive protein in cerebrospinal fluid from patients with spinal diseases

Citation
N. Natsume et al., Analysis of cartilage-derived retinoic acid-sensitive protein in cerebrospinal fluid from patients with spinal diseases, SPINE, 26(2), 2001, pp. 157-160
Citations number
12
Categorie Soggetti
Neurology
Journal title
SPINE
ISSN journal
03622436 → ACNP
Volume
26
Issue
2
Year of publication
2001
Pages
157 - 160
Database
ISI
SICI code
0362-2436(20010115)26:2<157:AOCRAP>2.0.ZU;2-V
Abstract
Study Design. The expression of cartilage-derived retinoic acid-sensitive p rotein (CD-RAP) was measured in cerebrospinal fluid from patients with spin al diseases. Objectives. To quantify the levels of CD-RAP in human cerebrospinal fluid a nd to clarify its character. Summary of Background Data. Cartilage-derived retinoic acid-sensitive prote in is a newly discovered, secreted molecule that is expressed during the ch ondrogenesis phase of endochondral bone formation and in articular cartilag e. In recent studies CD-RAP has been detected in the serum of patients with melanoma and breast cancer, and it has been used to monitor tumor activity . However, the function of CD-RAP is unknown, and the expression of CD-RAP in human cerebrospinal fluid has never been reported. Methods, The concentration of CD-RAP in human cerebrospinal fluid was measu red by enzyme-linked immunosorbent assay with antihuman CD-RAP antibodies. Cerebrospinal fluid samples were collected from two groups of patients. Gro up 1, the control group, consisted of 40 patients: 22 with trauma and 18 wi th gynecologic diseases. Group 2 consisted of 172 patients with spinal dise ases: 5 with meningioma, 5 with neurinoma, 5 with arachnoid cyst, 30 with c ervical spondylotic myelopathy, 35 with lumbar disc herniation, 56 with lum bar canal stenosis, and 36 with scoliosis. Results. The concentration of CD-RAP in the control group was 16.5 +/- 8.3 ng/mL. The concentrations of CD-RAP in Group 2 were: 35.3 +/- 14.7 ng/mL in meningioma, 23.5 +/- 7.41 ng/mL in neurinoma, 26.0 +/- 22.2 ng/mL in arach noid cyst, 41.7 +/- 22.3 ng/mL in cervical myelopathy, 27.8 +/- 14.7 ng/mL in lumbar disc herniation, 36.5 +/- 18.4 ng/mL in lumbar canal stenosis, an d 13.4 +/- 7.48 ng/mL in scoliosis, The concentrations of CD-RAP in cervica l myelopathy, lumbar canal stenosis, and lumbar disc herniation were signif icantly higher than in the control group (P < 0.001). Conclusions. The CD-RAP concentration was low in the control group, whereas it was significantly higher in spinal diseases that cause spinal stenosis. CD-RAP is expressed in cerebrospinal fluid as a result of damage to or str essing of neural structures and could be a marker for spinal diseases.